12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CTAP101: Phase IIb data

A double-blind, U.S. Phase IIb trial in 78 stage III or IV CKD patients with SHPT and vitamin D insufficiency showed that once-daily 30, 60 and 90 µg oral CTAP101 significantly reduced mean intact PTH levels from baseline to week 6 by 20%, 33% and 39%, respectively, vs. a 17% increase for placebo (p<0.005 for all). Additionally, 98% of patients receiving CTAP101 achieved...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >